Abstract:OBJECTIVE:To observe the effects of long-term cyclosporine A (CsA) treatment in 20 children with steroid-resistant idiopathic nephrotic syndrome (SRNS) and analyse the relevant influencing factors of CsA therapy. METHODS:Twenty children with SRNS received CsA therapy for 2 years between February 2001 and October 2006 in the Department of Nephrology. The mean age of children at initiation of CsA therapy was 5.5 years (30 months to 12 years). The initial renal histology showed minimal change (MCNS) in 15 patients, focal segmental glomerulosclerosis (FSGS) in 4 patients and mesangial proliferative glomerulonephritis (MsPGN) in one. The starting dose of CsA was 3 - 5 mg/(kg.d), adjusted to maintain a trough level of 100- 200 microg/L during the first 6 months. After one year, a low dose of CsA 1 - 3 mg/(kg.d) with a trough level of 40 - 70 microg/L was applied to maintain remission for 1 year. Liver function, serum albumin, serum cholesterol, serum creatinine, urinary NAG/Cr, 24 h urinary protein excretion and CsA whole blood trough level of the patients were monitored every one or three months. RESULTS:(1) Complete remission (proteinuria < or = 0.1 g/d or negative by dipstick for 3 consecutive days), partial remission (proteinuria between 0.1 g/d and 50 mg/(kg.d), serum albumin > or = 30 g/L) and resistance to CsA (proteinuria > or = 50 mg/(kg.d), or > or = 3+ by dipstick, after 6 months of CsA treatment over a trough level of 100 microg/L) were observed in 65%, 20% and 15%, respectively. Eleven patients who had complete remission discontinued CsA, in 5 (45%) patients the disease relapsed, and resumption of CsA therapy was followed by remission in three of them. (2) MCNS showed a 93% response to CsA therapy while non-MCNS showed a 60% response, but the difference was not significant (P > 0.05). (3) Hypertrichosis, gingival hyperplasia and hypertension occurred in 75%, 25% and 10% of the patients, respectively. Two patients were found to have renal impairment (> 30% rise of serum creatinine) and recovered in 2 weeks. Four patients showed a rise of urinary NAG/Cr. The central nervous system adverse event occurred in 2 cases. Post-therapy biopsies performed in 3 patients (2 with FSGS and one with MCNS) did not show any relevant tubulointerstitial fibrosis. Two patients with FSGS of the twenty cases progressed into end-stage renal failure. CONCLUSIONS:CsA treatment was confirmed to be effective in children with SRNS. Renal fibrosis was rare in patients treated with a low dose of CsA for 2 years.

Low-Dose Cyclosporine Treatment in Chinese Nephrotic Patients with Idiopathic Membranous Nephropathy: an Uncontrolled Study with Prospective Follow-Up

Preliminary observation of low-dose cyclosporine A combined with low-dose prednisone in the treatment of patients with idiopathic membranous nephropathy

Combined Immunosuppressive Treatment (CIST) in Lupus Nephritis: a Multicenter, Randomized Controlled Study.

Low-dose Cyclosporine in Treatment of Membranous Nephropathy with Nephrotic Syndrome: Effectiveness and Renal Safety

Early Initiation of Tacrolimus or Cyclophosphamide Therapy for Idiopathic Membranous Nephropathy with Severe Proteinuria.

Cyclosporin A Treatment for Idiopathic Membranous Nephropathy.

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy.

The Efficacy and Safety of Tacrolimus Monotherapy in Adult-Onset Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

Combination Therapy of Prednisone and Cyclophosphamide for Patients with Idiopathic Membranous Nephropathy:A Prospective Randomized Controlled Trial

CYCLOSPORINE A TREATMENT IN PATIENTS WITH MEMBRANOUS LUPUS NEPHROPATHY

Cyclosporine A in Treatment of Membranous Lupus Nephropathy

Long-term Effects of Cyclosporine A in Children with Steroid-Resistant Idiopathic Nephrotic Syndrome and Outcomes of the Patients

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.

Tacrolimus As a Steroid-Sparing Agent for Adults with Steroid-Dependent Minimal Change Nephrotic Syndrome

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.

Comparison of Dosage of Glucocorticoid in Idiopathic Membranous Nephropathy: A Systematic Review and Network Meta-Analysis

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial